PNTPENTAIR plc

NYSE pentair.com


$ 12.51 $ 0.02 (0.16 %)    

Tuesday, 26-Dec-2023 15:59:59 EST
QQQ $ 424.53 $ -0.76 (-0.18 %)
DIA $ 381.21 $ -0.26 (-0.07 %)
SPY $ 502.86 $ -1.54 (-0.31 %)
TLT $ 88.42 $ 0.22 (0.25 %)
GLD $ 213.31 $ 0.81 (0.38 %)
$ 12.5
$ 12.50
$ 0.00 x 0
$ 12.51 x 4,600
$ 12.49 - $ 12.51
$ 6.57 - $ 14.35
3,290,996
na
13.22B
$ 0.53
$ 21.24
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-23-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 10-24-2023 09-30-2023 10-Q
4 07-27-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-21-2023 12-31-2022 10-K
7 10-25-2022 09-30-2022 10-Q
8 07-26-2022 06-30-2022 10-Q
9 04-21-2022 03-31-2022 10-Q
10 02-22-2022 12-31-2021 10-K
11 10-26-2021 09-30-2021 10-Q
12 07-27-2021 06-30-2021 10-Q
13 04-22-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 10-20-2020 09-30-2020 10-Q
16 07-23-2020 06-30-2020 10-Q
17 04-30-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 10-23-2019 09-30-2019 10-Q
20 07-23-2019 06-30-2019 10-Q
21 04-23-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 10-23-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-20-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 10-24-2017 09-30-2017 10-Q
28 07-25-2017 06-30-2017 10-Q
29 04-25-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-25-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-26-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 10-20-2015 09-26-2015 10-Q
36 07-21-2015 06-27-2015 10-Q
37 04-21-2015 03-28-2015 10-Q
38 02-24-2015 12-31-2014 10-K
39 10-21-2014 09-27-2014 10-Q
40 07-31-2014 06-28-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 recent-ma-bodes-well-for-targeted-cancer-therapy-player-fusion-pharmaceuticals-analyst-say-astrazeneca-is-favorably-positioned

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted...

 brookline-capital-downgrades-point-biopharma-global-to-hold-lowers-price-target-to-125

Brookline Capital analyst Kemp Dolliver downgrades POINT Biopharma Global (NASDAQ:PNT) from Buy to Hold and lowers the price...

 lantheus-downgraded-due-to-reliance-on-pnt2002-analyst-cites-comparable-profile-to-novartis-drug

Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Ph...

 why-is-prostate-cancer-focused-lantheus-stock-trading-lower-today

Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SP...

Core News & Articles

Lantheus Holdings, Inc. (Lantheus) (NASDAQ:LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ:PNT) today announced statistic...

 top-5-health-care-stocks-that-may-collapse-in-november

As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

Core News & Articles

The tender offer, which was previously scheduled to expire at one minute past 11:59 p.m., Eastern time, on Nov. 9, 2023, has be...

 bvf-partners-lp-reports-165-stake-in-point-biopharma-global-as-of-nov-2-bvf-partners-purchased-point-biopharma-global-shares-based-on-belief-that-such-shares-when-purchased-were-undervalued

-SEC filing

 piper-sandler-downgrades-point-biopharma-global-to-neutral-announces-125-price-target

Piper Sandler analyst Edward Tenthoff downgrades POINT Biopharma Global (NASDAQ:PNT) from Overweight to Neutral and announce...

 raymond-james-downgrades-point-biopharma-global-to-market-perform

Raymond James analyst Rahul Sarugaser downgrades POINT Biopharma Global (NASDAQ:PNT) from Outperform to Market Perform.

 truist-securities-downgrades-point-biopharma-global-to-hold-lowers-price-target-to-125

Truist Securities analyst Nicole Germino downgrades POINT Biopharma Global (NASDAQ:PNT) from Buy to Hold and lowers the pric...

 jonestrading-downgrades-point-biopharma-global-to-hold

JonesTrading analyst Justin Walsh downgrades POINT Biopharma Global (NASDAQ:PNT) from Buy to Hold.

 crude-oil-moves-higher-point-biopharma-global-shares-jump

U.S. stocks extended losses toward the end of trading, with the S&P 500 falling around 1.5% on Tuesday. The Dow traded dow...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION